NEW YORK, May 11 – Merck has agreed to acquire Rosetta Inpharmatics in a stock-for-stock transaction worth $620 million, the companies said Friday.

The tax-free reorganization will swap each share of Rosetta stock for 0.2352 shares of Merck stock, giving a value of $18 per share of Rosetta stock, an 82 percent premium on Thursday’s closing price.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Robert Redfield is floated as the next director of the US Centers for Disease Control and Prevention, the Washington Post reports.

The New York Times writes that the National Institutes of Health's All of Us Research Program is "ambitious" and that some are concerned it might be overly so.

Representative Lamar Smith's criticism of the National Science Foundation has "changed the nature of the conversation," according to ScienceInsider.

In PLOS this week: non-coding RNA function in yeast, transcriptomic profiles of malaria parasites, and more.